WO2026092306 - ANTI-VEGF-A ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/092306
Publication Date
07.05.2026
International Application No.
PCT/CN2025/129706
International Filing Date
24.10.2025
Title **
[English]
ANTI-VEGF-A ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-VEGF-A ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
LAN, Weiqiu
LIU, Baihong
CHEN, Yang
YANG, Yi
Priority Data
PCT/CN2024/127938
29.10.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2180 | |
| EPO | Filing, Examination, Granting | 18579 | |
| Japan | Filing, Examination, Granting | 2553 | |
| South Korea | Filing, Examination, Granting | 3001 | |
| USA | Filing, Examination, Granting | 10540 |
Total:
36,853
Contact Us
Abstract[English]
Provided herein are anti-VEGF-A (vascular endothelial growth factor A) antibodies, antigen-binding fragments, and the uses thereof.[French]
La présente invention concerne des anticorps anti-VEGF-A (facteur de croissance vasculaire endothélial A), des fragments de liaison à l'antigène, et leurs utilisations.